DOI QR코드

DOI QR Code

Clinical Observation and Therapeutic Evaluation of Rh-endostatin Combined with DP Regimen in Treating Patients with Advanced Esophageal Cancer

  • Deng, Wen-Ying (Department of Gastroenterology, Hennan Cancer Hospital Affiliated to Zhengzhou University) ;
  • Song, Tao (Department of Radiology, Hennan Cancer Hospital Affiliated to Zhengzhou University) ;
  • Li, Ning (Department of Gastroenterology, Hennan Cancer Hospital Affiliated to Zhengzhou University) ;
  • Luo, Su-Xia (Department of Gastroenterology, Hennan Cancer Hospital Affiliated to Zhengzhou University) ;
  • Li, Xiang (Department of Radiology, Hennan Cancer Hospital Affiliated to Zhengzhou University)
  • Published : 2014.08.30

Abstract

Objective: To observe the curative effects of rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer and analyze the correlation of CT perfusion (CTP) parameters and the expression of vascular endothelial growth factor (VEGF). Methods: Twenty patients with esophageal cancer confirmed pathologically were randomly divided into combined treatment (rh-endostatin+DP regimen) group and single chemotherapy group, 10 patients in each group, respectively. All patients were given conventional CT examination and CTP imaging for primary tumor. The level of VEGF, the size of tumor and CTP parameters (BF, BV, PS and MTT) before treatment and after 2 cycles of treatment were determined for the comparison and the correlation between CTP parameters and VEGF expression was analyzed. Results: the therapeutic effect of rh-endostatin+DP regimen group was superior to single chemotherapy group. VEGF level after treatment in rh-endostatin+DP regimen group was obviously lower than single chemotherapy group (P<0.01). The expression of VEGF had positive correlation with BF and BV but negative correlation with MTT. Compared with treatment before for rh-endostatin+DP regimen group, BF, BV and PS decreased while MTT increased after treatment (P<0.05). However, there were no significant differences between treatment before and after treatment in single chemotherapy (P>0.05). Conclusions: Rh-endostatin can down-regulate the expression of VEGF in esophageal cancer, change the state of hypertransfusion and high permeability of tumor vessels and had the better curative effect and slighter adverse reactions when combined with chemotherapy.

Keywords

Esophageal cancer;endostatin;CT perfusion;normalization

References

  1. Jiang C, Liao FX, Rong YM, et al (2014). Efficacy of Taxane- Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer. Asian Pac J Cancer Prev, 15, 5493-8. https://doi.org/10.7314/APJCP.2014.15.13.5493
  2. Liang JF, Pan MY (2005). Research progress of endostatin. Milit Med J Southeast China, 7, 475-8.
  3. Liu JL, Zhou LL, Cai MH, et al (2009). Observation on the short-term effect of nedaplatin plus tegafur in the treatment of advanced esophageal carcinoma. J Pract Oncol, 24, 515-6.
  4. Liu C, Jiang Z, Deng QX, et al (2014). Meta-analysis of Association Studies of CYP1A1 Genetic Polymorphisms with Digestive Tract Cancer Susceptibility in Chinese. Asian Pac J Cancer Prev, 15, 4689-95. https://doi.org/10.7314/APJCP.2014.15.11.4689
  5. Mai RQ, Huang B, Shen L, et al (2014). Genotype distribution of human papillomavirus in women with abnormal cervical cytology in an esophageal carcinoma high incidence area of china. Asian Pac J Cancer Prev, 15, 4945-50. https://doi.org/10.7314/APJCP.2014.15.12.4945
  6. Malik MA, Umar M, Gupta U, et al (2014). Phospholipase C epsilon 1 (PLCE1 rs2274223A>G, rs3765524C>T and rs7922612C>T) polymorphisms and esophageal cancer risk in the Kashmir Valley. Asian Pac J Cancer Prev, 15, 4319-23. https://doi.org/10.7314/APJCP.2014.15.10.4319
  7. Mizobuchi H, Garcia-Castellano JM, Philip S, et al (2008). Hypoxia markers in human osteosarcoma, an exploratory study. Clin Orthop Relat Res, 466, 2052-9. https://doi.org/10.1007/s11999-008-0328-y
  8. Shan BE, Pan LF, Li QX, et al (2005). Study on the expression of VEGF in human esophageal cancer tissue. Cancer Res Prev Treat, 32, 644-7.
  9. Somi MH, Golzari M, Farhang S, et al (2014). Gastrointestinal cancer incidence in East Azerbaijan, Iran, update on 5 year incidence and trends. Asian Pac J Cancer Prev, 15, 3945-9. https://doi.org/10.7314/APJCP.2014.15.9.3945
  10. Stefani ED, Boffetta P, Ronco AL, et al (2014). Processed meat consumption and squamous cell carcinoma of the oesophagus in a large case-control study in uruguay. Asian Pac J Cancer Prev, 15, 5829-33. https://doi.org/10.7314/APJCP.2014.15.14.5829
  11. Andrea K, Krin W, Andreas O, et al (1999). Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 85, 178-87. https://doi.org/10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7
  12. Bondestam J, Salven P, Jaaskela-Saari H, et al (2000). Major surgery increases serum levels of vascular endothelial growth factor only temporarily. Am J Surg, 179, 57-9. https://doi.org/10.1016/S0002-9610(99)00253-6
  13. Bellomi M, Petralia G, Sonzogni A, et al (2007). CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology, 244, 486-93. https://doi.org/10.1148/radiol.2442061189
  14. Chen LQ (2010). International TND installment interpretation and evaluation for esophageal cancer. Chin J Oncol, 32, 237-40.
  15. Cao DD, Ge W, Wang HM, ea al (2011). Efficacy and Safety of rh-endosratin combined with chemotherapy versus chemotherapy alone for asvanced NSCLC, a metaoanalysis review. Chin J Lung Cancer, 14, 404-13.
  16. Carmeliet P, Jain RK (2011). Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov, 10, 417-27. https://doi.org/10.1038/nrd3455
  17. Folkman J (2007). Angiogenesis, an organizing principle for drug discovery? Nat Rev Drug Discov, 6, 273-86. https://doi.org/10.1038/nrd2115
  18. Huang JY1, Sun Y, Fan QX, Zhang YQ (2009). Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer, a randomized control trial. Zhong Xi Yi Jie He Xue Bao, 7, 1047-51. https://doi.org/10.3736/jcim20091105
  19. Inoue K1, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S (1997). Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer, 79, 206-13. https://doi.org/10.1002/(SICI)1097-0142(19970115)79:2<206::AID-CNCR2>3.0.CO;2-I
  20. Kozlowski M, Naumnik W, Niklinski J, et al (2010). Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer. Neoplasma, 58, 311-9.
  21. Sun S, Schiller JH (2007). Angiogenesis inhibitor in the treatment of lung cancer. Crit Rev Oncol Hematol, 62, 93-104. https://doi.org/10.1016/j.critrevonc.2007.01.002
  22. Sun Y, Shi KY (2007). Manual Medical Oncology. People's Medical Publishing House, 7, 135-45.
  23. Shao MW, Qiu JR, Wu H, et al (2014). Mechanism of Shenyi Capsule Concomitant with Endostar and Chemotherapy on the Growth and Apoptosis of MCF-7 Breast Cancer Cells. J Int Transl Med, 2, 299-302.
  24. Wang J, Yu JM, Jing SW, et al (2014). Relationship between EGFR Over-expression and Clinicopathologic Characteristics in Squamous Cell Carcinoma of the Esophagus, A Meta analysis. Asian Pac J Cancer Prev, 15, 5889-93. https://doi.org/10.7314/APJCP.2014.15.14.5889
  25. Wang JW, Yang L (2003). Endostatin and Advances in Its Clinical Research. J Clin Res, 20, 778-81.
  26. Wu J, Long Q, Xu S, et al (2009). Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. J Biomech, 42, 712-21. https://doi.org/10.1016/j.jbiomech.2009.01.009
  27. Yan J, Zeng YX (2000). The latest guideline for response evaluation criteria in solid tumors. Foreign Med Sci (Cancer Section), 27, 375-6.
  28. Yang L, Wang JW, Cui XC (2005). Rh-endostatin (YH-16) in combination with vinorebine and cisplatin for advanced non-small cell lung cancer, a multicenter phase IItrial. Chin J New Drugs, 14, 204-7.
  29. Yang L, Wang JW, Sun Y, et al (2006). Ramdomized phase IItrial on escalated doses of rhendosstatin (YH-16) for advanced non-small cell lung cancer. Chin J Oncol, 28, 138-41.
  30. Yang JZ, Ji AF, Wang JS, et al (2014). Association between Ras association domain family 1A promoter methylation and esophageal squamous cell carcinoma, a meta-analysis. Asian Pac J Cancer Prev, 15, 3921-5. https://doi.org/10.7314/APJCP.2014.15.9.3921
  31. Yuan P, Chen TH, Chen ZW, et al (2014). Calculation of life-time death probability due malignant tumors based on a sampling survey area in China. Asian Pac J Cancer Prev, 15, 4307-9. https://doi.org/10.7314/APJCP.2014.15.10.4307
  32. Zhang JE, Liang CH, Zhao ZJ, et al (2006). Utility of CT perfusion in pulmonary nodules. Chin J Radiol, 39, 1041-5.
  33. Zhao L, Wei ZB, Yang CQ, et al (2014). Effects of PLCE1 Gene Silencing by RNA Interference on Cell Cycling and Apoptosis in Esophageal Carcinoma Cells. Asian Pac J Cancer Prev, 15, 5437-42. https://doi.org/10.7314/APJCP.2014.15.13.5437
  34. Zheng NG, Wang JL, Yang SL, et al (2014). Aberrant Epigenetic Alteration in Eca9706 Cells Modulated by Nanoliposomal Quercetin Combined with Butyrate Mediated via Epigenetic- NF-${\kappa}B$ Signaling. Asian Pac J Cancer Prev, 15, 4539-43. https://doi.org/10.7314/APJCP.2014.15.11.4539

Cited by

  1. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01) vol.142, pp.10, 2017, https://doi.org/10.1002/ijc.31217